GRAIL Announces Significant Progress with Multi-Cancer Early Detection Test Including FDA Breakthrough Device Designation
Liquid biopsy company GRAIL announced today that its multi-cancer test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration. This investigational blood test is in development for the early detection of multiple cancer types in individuals aged 50 and over. The FDA grants Breakthrough designation to devices that have the potential to provide for more effective diagnosis of life-threatening diseases such as cancer. “We’re excited the FDA recognizes the potential of our multi-cancer early detection blood test,” said GRAIL CEO Jennifer Cook. “There...